Literature DB >> 28130604

[Adjuvants].

R Brehler1.   

Abstract

It is estimated that only 5% of all patients who can principally benefit from specific immunotherapy (SIT) undergo this treatment. SIT represents the only curative treatment for allergic disorders and efficacy has been demonstrated with various allergens. There is an urgent demand for the development of safe preparations with enhanced efficacy achievable by only a few administrations. Adjuvants are pharmacological or immunological acting molecules modifying the specific immunological response to allergens. In vaccine technology, adjuvants are broadly used to enhance immunogenicity of highly purified antigens with low immune stimulating activity. Adjuvants may target to a retarded allergen release, a modulation of the immune system, or can be used as vector systems to transport allergens and adjuvants effectively to target cells.

Entities:  

Keywords:  Allergen immunotherapy; Allergy; Antigens; Immunostimulation; Vector systems

Mesh:

Substances:

Year:  2017        PMID: 28130604     DOI: 10.1007/s00105-017-3935-2

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  40 in total

Review 1.  The Use of Adjuvants for Enhancing Allergen Immunotherapy Efficacy.

Authors:  Julie Chesné; Carsten B Schmidt-Weber; Julia Esser von-Bieren
Journal:  Immunol Allergy Clin North Am       Date:  2016-02       Impact factor: 3.479

Review 2.  Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.

Authors:  Heather L Wilson; Arshud Dar; Scott K Napper; A Marianela Lopez; Lorne A Babiuk; George K Mutwiri
Journal:  Int Rev Immunol       Date:  2006 May-Aug       Impact factor: 5.311

3.  Effect of Lactobacillus rhamnosus GG and vitamin D supplementation on the immunologic effectiveness of grass-specific sublingual immunotherapy in children with allergy.

Authors:  Joanna Jerzynska; Wlodzimierz Stelmach; Joanna Balcerak; Katarzyna Woicka-Kolejwa; Blazej Rychlik; Andrzej Blauz; Marcin Wachulec; Piotr Stelmach; Pawel Majak; Iwona Stelmach
Journal:  Allergy Asthma Proc       Date:  2016-07       Impact factor: 2.587

4.  Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.

Authors:  Pascal Demoly; Waltraud Emminger; Dorte Rehm; Vibeke Backer; Lene Tommerup; Jörg Kleine-Tebbe
Journal:  J Allergy Clin Immunol       Date:  2015-08-17       Impact factor: 10.793

5.  A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines.

Authors:  A W Wheeler; J S Marshall; J T Ulrich
Journal:  Int Arch Allergy Immunol       Date:  2001-10       Impact factor: 2.749

6.  Administration of a probiotic with peanut oral immunotherapy: A randomized trial.

Authors:  Mimi L K Tang; Anne-Louise Ponsonby; Francesca Orsini; Dean Tey; Marnie Robinson; Ee Lyn Su; Paul Licciardi; Wesley Burks; Susan Donath
Journal:  J Allergy Clin Immunol       Date:  2015-01-13       Impact factor: 10.793

7.  Efficacy of a short course of specific immunotherapy in patients with allergic rhinoconjunctivitis to ragweed pollen.

Authors:  Piyush Patel; Tom Holdich; Karl J Fischer von Weikersthal-Drachenberg; Birgit Huber
Journal:  J Allergy Clin Immunol       Date:  2013-07-16       Impact factor: 10.793

8.  Antigen depot is not required for alum adjuvanticity.

Authors:  Sharon Hutchison; Robert A Benson; Vivienne B Gibson; Abigail H Pollock; Paul Garside; James M Brewer
Journal:  FASEB J       Date:  2011-11-21       Impact factor: 5.191

9.  Protein coated microcrystals formulated with model antigens and modified with calcium phosphate exhibit enhanced phagocytosis and immunogenicity.

Authors:  Sarah Jones; Catpagavalli Asokanathan; Dorota Kmiec; June Irvine; Roland Fleck; Dorothy Xing; Barry Moore; Roger Parton; John Coote
Journal:  Vaccine       Date:  2013-10-10       Impact factor: 3.641

10.  House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis.

Authors:  Y Okamoto; S Fujieda; M Okano; Y Yoshida; S Kakudo; K Masuyama
Journal:  Allergy       Date:  2016-08-23       Impact factor: 13.146

View more
  1 in total

Review 1.  Adjuvants for allergy immunotherapeutics.

Authors:  Carlos Gamazo; Carmen D'Amelio; Gabriel Gastaminza; Marta Ferrer; Juan M Irache
Journal:  Hum Vaccin Immunother       Date:  2017-10-03       Impact factor: 3.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.